Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
184.11B
Market cap184.11B
Price-Earnings ratio
26.43
Price-Earnings ratio26.43
Dividend yield
2.78%
Dividend yield2.78%
Average volume
3.06M
Average volume3.06M
High today
$345.50
High today$345.50
Low today
$338.07
Low today$338.07
Open price
$340.59
Open price$340.59
Volume
2.52M
Volume2.52M
52 Week high
$353.25
52 Week high$353.25
52 Week low
$261.43
52 Week low$261.43

Stock Snapshot

With a market cap of 184.11B, Amgen(AMGN) trades at $342.07. The stock has a price-to-earnings ratio of 26.43 and currently yields dividends of 2.8%.

During the trading session on 2026-02-02, Amgen(AMGN) shares reached a daily high of $345.50 and a low of $338.07. At a current price of $342.07, the stock is +1.2% higher than the low and still -1.0% under the high.

Trading volume for Amgen(AMGN) stock has reached 2.52M, versus its average volume of 3.06M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $353.25 and a low of $261.43.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $353.25 and a low of $261.43.

AMGN News

Simply Wall St 1d
Assessing Amgen Valuation After Recent Share Price Momentum And Pipeline Expectations

Advertisement Why Amgen (AMGN) Is Getting Attention Now Amgen (AMGN) is back on many watchlists after a period where its share price, recent returns and funda...

Assessing Amgen Valuation After Recent Share Price Momentum And Pipeline Expectations
Simply Wall St 2d
Amgen Lawsuit And Eczema Drug Exit Reframe Risk And R&D Priorities

Amgen (NasdaqGS:AMGN) is being sued over its decision to withdraw certain discounted drug prices from Sagebrush Health Services, a clinic serving underserved pa...

Amgen Lawsuit And Eczema Drug Exit Reframe Risk And R&D Priorities
Benzinga 3d
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends

Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ:AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration. • Amgen stock...

Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends

Analyst ratings

48%

of 33 ratings
Buy
45.5%
Hold
48.5%
Sell
6.1%

More AMGN News

Investor's Business Daily 3d
Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season

IBD Industry Themes Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season Licensing Biotech stocks continue to outperform in the cur...

Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season
Nasdaq 3d
Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab

(RTTNews) - Kyowa Kirin Co., Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab, with the Ja...

Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab
TipRanks 3d
Kyowa Kirin to regain control of rocatinlimab development, commercialization

Kyowa Kirin (KYKOF) announced the termination of the current rocatinlimab development and commercialization collaboration with Amgen. Kyowa Kirin will regain co...

Nasdaq 4d
Upcoming Dividend Run For AMGN?

This morning a "Potential Dividend Run Alert" went out for Amgen Inc (NASD: AMGN), at our DividendChannel.com Dividend Alerts service (a free email alerts featu...

Upcoming Dividend Run For AMGN?
TipRanks 4d
Amgen price target raised to $400 from $380 at Oppenheimer

Oppenheimer raised the firm’s price target on Amgen (AMGN) to $400 from $380 and keeps an Outperform rating on the shares ahead of quarterly results. The firm e...

Nasdaq 4d
Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.

Key Points Eli Lilly's stock trades at more than 30 times forward earnings, which is a steep price to pay right now. Amgen is a much cheaper option by compari...

Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.
Simply Wall St 6d
Is It Time To Reassess Amgen After Strong Multi Year Share Price Gains

If you are wondering whether Amgen's current share price lines up with its underlying value, you are not alone. This article is built to walk you through that q...

Is It Time To Reassess Amgen After Strong Multi Year Share Price Gains

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.